Cellular therapy updates in b‐cell lymphoma: The state of the car‐t

Zachary D. Crees, Armin Ghobadi

Research output: Contribution to journalReview articlepeer-review


Non‐Hodgkin Lymphoma accounts for >460,000 cases and >240,000 deaths globally and >77,000 cases and >20,000 deaths in the U.S. annually, with ~85% of cases being B‐cell malignancies. Until recently, patients with relapsed/refractory B‐cell lymphoma following standard chemotherapy in combination with anti‐CD20 monoclonal antibodies and autologous stem cell transplantation experienced a median overall survival (OS) of <6 months. However, with the approval of four different CD‐19 CAR‐T therapies between 2017 and 2021, approximately 60–80% of patients receiving CAR‐T therapy now achieve an objective response with >3 years median OS. Here, we review the current state of the art of CD19 CAR‐T therapies for B‐cell lymphomas, focusing on current updates in US FDA‐approved products, along with their associated efficacy and toxicities. Lastly, we high-light a selection of promising clinical developments in the field, including various novel strategies to increase CAR‐T therapy efficacy while mitigating toxicity.

Original languageEnglish
Article number5181
Issue number20
StatePublished - Oct 1 2021


  • Adoptive cell therapy
  • Axicabtagene ciloleucel
  • Brexucabtagene autoleucel
  • B‐cell lymphoma
  • CAR‐T cell
  • Chimeric antigen receptor
  • Cytokine release syndrome
  • Immune effector cell‐associated neurotoxicity syndrome
  • Lisocabtagene maraleucel
  • Tisagenlecleucel


Dive into the research topics of 'Cellular therapy updates in b‐cell lymphoma: The state of the car‐t'. Together they form a unique fingerprint.

Cite this